RxDoctor Payments Data

Jason Holbrook, MD

Internal Medicine · Roswell, GANPI 1073617692

Payments from drug & device makers

$9,322in general payments, 2019–2025

Across 537 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • Merz North America, Inc.$937
  • Amarin Pharma, Inc.$504
  • Kowa Pharmaceuticals America, Inc.$369
  • Amgen$351
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$9,308100%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,322 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$171,883
Medicare patients
393
Services billed
3,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$101,711
JanuviaSitagliptin Phosphate69$93,390
FarxigaDapagliflozin Propanediol38$43,167
JardianceEmpagliflozin23$27,888
JanumetSitagliptin Phos/Metformin Hcl14$16,900
TrulicityDulaglutide11$16,315
MounjaroTirzepatide13$16,100
ArexvyRsvpref3 Antigen/As01e/Pf34$10,385
SynthroidLevothyroxine Sodium55$6,396
Colesevelam Hcl12$5,799
Advair HfaFluticasone Propion/Salmeterol11$4,710
Atorvastatin Calcium537$4,020
Valsartan86$2,471
Nebivolol Hcl41$2,329
Levothyroxine Sodium252$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$165$110,29083 claims
Novo NordiskOzempic$1,361$101,71173 claims
AstraZenecaFarxiga$70$43,16738 claims
Lilly USA, LLCTrulicity, Mounjaro$231$32,41524 claims
Boehringer IngelheimJardiance$82$27,88823 claims
GSKArexvy$317$10,38534 claims
AbbVieSynthroid$3,126$6,39655 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$100$2,226252 claims
PfizerPaxlovid$169$1,42923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →